Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  Akt inhibitor MK2206
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 26 for your search:
Start Over
Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02675, CDR0000701372, NCCTG-N1087, N1087, U10CA180821, U10CA025224, NCT01369849
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10-067, NCT01169649
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2010-02270, MDA-2010-0247, CDR0000688457, 2010-0247, 8727, N01CM00038, N01CM00039, N01CM62202, P30CA016672, NCT01239342
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: Adult
Sponsor: NCI
Protocol IDs: NCI-2011-02619, SWOG-S1005, CDR0000689602, S1005, U10CA180888, U10CA032102, NCT01260701
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02648, CDR0000689613, ECOG-E2809, E2809, U10CA180820, U10CA021115, NCT01251861
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02892, CDR0000694003, N01CM00039, P30CA016672, MDACC 2010-0242, 2010-0242, 8732, N01CM62202, U01CA062490, NCT01277757
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00549, 10-402, 8729, P30CA006516, NCT01283035
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02578, CDR0000695056, CHNMC-PHII-108, PhII-108, 8698, N01CM00038, N01CM00071, N01CM62209, P30CA033572, NCT01294306
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2010-02186, 2010-0243, 8731, N01CM00039, NCT01253447
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2013-00521, 10-258, 8760, P30CA006516, U01CA062490, UM1CA186709, DFCI-10258, NCT01307631
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02581, CDR0000696863, MC1079, 8761, P30CA015083, N01CM00099, MAYO-MC1079, NCT01349933
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02974, OSU-10104, CDR0000698451, 8735, N01CM00070, P30CA016058, NCT01425879
MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110117, 11-C-0117, NCT01333475
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01966, CDR0000733948, CALGB-A091104, A091104, N01CM62206, R01CA166978, U10CA031946, U10CA180821, NCT01604772
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01993, SWOG-S1115, CDR0000737878, S1115, U10CA180888, U10CA032102, NCT01658943
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02890, NCI-2011-00275, 2010-0261, 8728, N01CM00039, P30CA016672, N01CM62202, NCT01258998
A Phase I Study of MK2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (2206-003 AM5)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 91
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2206-003, 2009_547, NCT00848718
A Study of MK2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (2206-015)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2206-015, 2009_646, NCT00963547
Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Other
Protocol IDs: 201001017M, NCT01147211
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI
Protocol IDs: NCI-2011-02612, CDR0000687929, COG-ADVL1013, ADVL1013, U01CA097452, NCT01231919
Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02550, WCCC-CO-10904, CDR0000688912, CO10904, 8709, P30CA014520, U01CA062491, NCT01245205
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10998, NCT01235897
MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02562, CDR0000690723, 2010-0245, 8739, P30CA016672, U01CA062461, U01CA062490, MDA-2010-0245, NCT01263145
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02574, WSU# 2010-109, CDR0000693729, 2010-109, 8747, P30CA022453, U01CA062487, U01CA062490, NCT01281163
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8669-049, NCT01295632
Start Over